Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorKaplan, S.en
dc.contributor.authorHanauske, A. R.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBruntsch, U.en
dc.contributor.authorte Velde, A.en
dc.contributor.authorWanders, J.en
dc.contributor.authorHeinrich, B.en
dc.contributor.authorVerweij, J.en
dc.date.accessioned2015-11-24T18:51:27Z
dc.date.available2015-11-24T18:51:27Z
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18263
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/adverse effects/*therapeutic useen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapyen
dc.subjectFemaleen
dc.subjectHematopoiesis/drug effectsen
dc.subjectHumansen
dc.subjectLactones/adverse effects/therapeutic useen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMacrolidesen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.titleSingle agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Groupen
heal.abstractIn a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m-2 once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows activity in patients with advanced NSCLC.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8562351-
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1996-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Pavlidis-1996-single agent activity.pdf
Μέγεθος:
612.33 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ